Results 41 to 50 of about 30,645 (194)

Lower mutation frequency of BCP/precore regions in e antigen-negative chronic HBV-infected children instead of adults patients.

open access: yesPLoS ONE, 2015
To describe the Hepatitis B e antigen(HBeAg) seroconversion related mutation profiles of the basal core promoter(BCP)/precore regions in e antigen seroconverted child patients, a cohort of 245 child patients with CHB and a control patients group of 92 ...
Yong Huang   +7 more
doaj   +1 more source

Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B

open access: yesGut and Liver, 2016
Background/AimsDespite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion.
Chung-Il Wi   +4 more
doaj   +1 more source

The Emerging Role of China in the Innovation, Individualization, and Translation of Antiviral Therapeutics for Chronic Hepatitis B

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
This perspective outlines China's contributions toward functional‐cure‐oriented antiviral therapies for chronic hepatitis B, summarizing key clinical data on bepirovirsen and domestic drug pipelines with balanced coverage of both promising and disappointing trial results.
Dandan Weng, Zhujun Cao, Qing Xie
wiley   +1 more source

Forest plot for HBeAg seroconversion rates 48 weeks post therapy.

open access: yes, 2014
Forest plot for HBeAg seroconversion rates 48 weeks post therapy.
Chi Zhang (9857)   +6 more
core   +1 more source

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients [PDF]

open access: yes, 2018
BACKGROUND: Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful.
Yuen, L   +16 more
core   +1 more source

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice

open access: yesInternational Journal of Infectious Diseases, 2017
Aim: This study developed and validated a non-invasive scoring model to predict 1-year hepatitis B e antigen (HBeAg) seroconversion in response to nucleos(t)ide analog (NA) treatment in NA-naïve patients with HBeAg-positive chronic hepatitis B (CHB ...
Mingfan Geng   +9 more
doaj   +1 more source

Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 420-434, March 2025.
ABSTRACT Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
Clémence Boivin‐Champeaux   +6 more
wiley   +1 more source

Forest plot for HBeAg seroconversion rates 24 weeks post therapy.

open access: yes, 2014
Forest plot for HBeAg seroconversion rates 24 weeks post therapy.
Chi Zhang (9857)   +6 more
core   +1 more source

Prevalence and clinical significance of HBeAg-positive chronic hepatitis B patients with and without anti-HBe antibody

open access: yesVirulence
The clinical significance of the coexistence of hepatitis B e antigen (HBeAg) and antibodies against HBeAg (anti-HBe) in patients with chronic hepatitis B (CHB) remains unclear.
Ruifei Xue   +14 more
doaj   +1 more source

Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study

open access: yesVirology Journal, 2011
Background Adefovir Dipivoxil (ADV) is an important agent to suppress hepatitis B virus (HBV) replication with suboptimal effect on virological and serological response.
Zhang Jing   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy